AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
- Details
- Category: AstraZeneca
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD.
Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
- Details
- Category: Novo Nordisk
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)(1), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.
Novartis appoints Bertrand Bodson as Chief Digital Officer
- Details
- Category: Novartis
Novartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis. He will join Novartis on January 1, 2018, and will be responsible for creating and executing a company-wide digital strategy in close collaboration with the Executive Committee of Novartis,
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
- Details
- Category: AstraZeneca
AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking low-dose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.
Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer
- Details
- Category: Pfizer
The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, have announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE®).
Amgen and Humana partner for improved health outcomes and efficiency
- Details
- Category: Amgen
Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health outcomes and improve efficiency by unlocking new insights from the real world health care experiences of Humana's 13 million members.
More Pharma News ...
- Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
- Lyfebulb-Novo Nordisk Innovation Award 2017
- Repatha® (evolocumab) phase 3 cognitive function study results published in the New England Journal of Medicine
- Bristol-Myers Squibb announces topline results from CheckMate -214
- Boehringer Ingelheim achieves good growth in the first half of 2017
- FDA Advisory Committee votes in favor of XELJANZ® (tofacitinib citrate) for the treatment of active psoriatic arthritis
- Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity